Abstract
Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis.
Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa.
Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series.
The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
Keywords: Inflammation, immuno-mediated disease, anti-TNF-alpha, off-label use.
Current Drug Safety
Title:Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Volume: 11 Issue: 1
Author(s): Giulia Ganzetti, Anna Campanati, E. Molinelli and A. Offidani
Affiliation:
Keywords: Inflammation, immuno-mediated disease, anti-TNF-alpha, off-label use.
Abstract: Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis.
Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa.
Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series.
The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
Export Options
About this article
Cite this article as:
Ganzetti Giulia, Campanati Anna, Molinelli E. and Offidani A., Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014121732
DOI https://dx.doi.org/10.2174/1574886310666151014121732 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenomics in Aspirin Intolerance
Current Drug Metabolism Anti-inflammatory, Antioxidant, Lung and Liver Protective Activity of <i>Galaxaura oblongata</i> as Antagonistic Efficacy against LPS using Hematological Parameters and Immunohistochemistry as Biomarkers
Cardiovascular & Hematological Agents in Medicinal Chemistry The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells
Anti-Cancer Agents in Medicinal Chemistry Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Angiogenin as a Molecular Target for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Nuclear Medicine: from Photons to Physiology
Current Pharmaceutical Design Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Current Drug Metabolism S100A8 and S100A9 Overexpression Is Associated with Poor Pathological Parameters in Invasive Ductal Carcinoma of the Breast
Current Cancer Drug Targets